REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Signing of Strategic Platform License

MaxCyteAnnouncement

02/04/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB9563Ia&default-theme=true

RNS Number : 9563I  MaxCyte, Inc.  02 April 2024

 

 

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the
Development of Engineered B Cell Medicines (BCMs)

 

Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™
platform within its Engineered B Cell Medicines programs

 

Rockville, MD, April 2, 2024 - MaxCyte, Inc. (https://maxcyte.com/) ,
(Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications and Be Biopharma (https://be.bio/) ("Be
Bio"), a company pioneering the development of Engineered B Cell Medicines
(BCMs) to dramatically improve the lives of patients who are living with
genetic diseases, cancer, and other serious conditions, today announced the
signing of a strategic platform license (SPL) to support the development of Be
Bio's BCMs programs.

 

Under the terms of the agreement, Be Bio obtains non-exclusive research,
clinical and commercial rights to use MaxCyte's Flow Electroporation®
technology and ExPERT™ platform. In return, MaxCyte is entitled to receive
annual licensing fees and program-related revenue.

 

 "We are thrilled to support Be Bio's pioneering efforts in the creation of
Engineered B Cell Medicines (BCMs)," said Maher Masoud, President and CEO of
MaxCyte. "Our technology and expertise will empower them to unlock the
potential of human B cells to address the unmet medical needs of patients with
genetic diseases, cancer, and beyond. This new class of therapies could be
transformative, and we are excited to be part of this journey."

 

MaxCyte's ExPERT™ instrument portfolio is the next generation of leading,
clinically-validated electroporation technology for complex and scalable cell
engineering. By delivering high transfection efficiency, seamless scalability
and enhanced functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and cellular
therapeutics. Be Bio is MaxCyte's 27(th) clinical/commercial partnership
overall, each of which generates pre-commercial milestone revenue, the vast
majority of which include sales-based payments.

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on X
(https://twitter.com/MaxCyte_info) (formerly Twitter) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

 

 

About Be Biopharma

 

Be Biopharma ("Be Bio") is pioneering Engineered B Cell Medicines (BCMs) to
dramatically improve the lives of patients who are living with Hemophilia B
and other genetic diseases, cancer, and other serious conditions. With eyes
locked on the patient, our team of purpose-driven scientists, technologists,
manufacturing experts and business builders collaborate to create a bold new
class of cell therapies. Be Bio was founded in October 2020 by B cell
engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., from
Seattle Children's Research Institute. Be Bio is backed by ARCH Venture
Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund,
Bristol Myers Squibb, Takeda Ventures, Seattle Children's Research Institute
and others. Since our founding, Be Bio's investors have committed over $180
million to enable the Company to re-imagine medicine based on the power of B
cell therapy. For more information, please visit us at be.bio
(https://be.bio/) and our LinkedIn
(https://www.linkedin.com/company/be-biopharma-inc) page.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Seismic Collaborative

Anya Bolshem
abolshem@spectrumscience.com (mailto:abolshem@spectrumscience.com)

+1 732-284-1751

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

Be Bio Contacts:

 

Investor Relations

ir@be.bio

 

Media:

media@be.bio

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCITMLTMTJMMBI